We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Joerg Herrmann MD

Joerg Herrmann MD

Professor of Medicine, Mayo Graduate School of Medicine, Rochester, Minnesota

Dr. Joerg Herrmann received his medical training at Ruhr University, Bochum, Germany, and completed his internship in internal medicine at the University Clinic in Essen. Following a postdoctoral research fellowship, he pursued the clinician–investigator track in internal medicine-cardiology, and further training in interventional cardiology at the Mayo Clinic, Rochester, Minnesota. He then joined the staff of the Department of Cardiovascular Diseases at the Mayo Clinic, Rochester. Currently, he is a Professor of Medicine at the Mayo Graduate School of Medicine and serves as the director of the Cardio-Oncology Clinic and the research director of the Ischemic Heart Disease program.

Dr. Herrmann has been receiving NIH research funding, serves as a reviewer for over 30 journals, including all major cardiovascular journals.  He currently is the chair of the Scientific Committee of the International Cardio-Oncology Society and an associated editor of several journals including the European Heart Journal (EHJ), EHJ Open, Trends in Cardiovascular Medicine, International Journal of Cardiology, Frontiers in Cardiovascular Medicine, and Current Cardiology Reports. He is also a regular contributor to Braunwald's Heart Disease, the associated editor of Trends in Cardiovascular Medicine, and the editor of the Cardio-Oncology Companion Book to Braunwald’s Heart Disease as well as the textbook Clinical Cardio-Oncology.

His main research interests are cardio-oncology, cardiac biomarkers, periprocedural myocardial infarction, atherosclerosis, and vascular biology.

Disclosures

Dr. Joerg Herrmann participated in the 2014 and 2016 Ponatinib in CML Cardio-Oncology Advisory Board meeting organized by ARIAD Pharmaceuticals, the 2016 Carfilzomib Advisory Board meeting organized by Amgen and is a member of the Institute for Cardio-Oncology advisory panel sponsored by Bristol-Myers Squib. He also reports disclosures from Pfizer. 

Recent Contributions to PracticeUpdate:

  1. Incidence of Cardiovascular Events in Patients Treated With Immune Checkpoint Inhibitors
  2. SGLT2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines
  3. FFR-Guided Stenting or Coronary Bypass Surgery for Better Quality of Life
  4. Preservation of Cardiac Function After Myocardial Infarction
  5. FFR-Guided vs IVUS-Guided PCI in Intermediate Coronary Artery Stenosis
  6. ACC 2022: Recommendations From Dr. Joerg Herrmann
  7. 2021 Top Story in Cardiology: EMPEROR-Preserved—Empagliflozin in HFpEF
  8. Similar 5-Year All-Cause Death Between PCI and CABG
  9. ESC 2021: Recommendations From Dr. Joerg Herrmann
  10. Characteristics and Outcomes of Women Developing Heart Failure After Early-Stage Breast Cancer Chemotherapy

Elsewhere

Most Read This Week

Recently Updated